Research ArticleDrug Discovery and Translational Medicine
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, John Gatfield, Christoph Boss, Markus von Raumer, Benno Schindelholz, Clemens Muehlan, Joop van Gerven and Francois Jenck
Journal of Pharmacology and Experimental Therapeutics September 2017, 362 (3) 489-503; DOI: https://doi.org/10.1124/jpet.117.241596
Alexander Treiber
Departments of Preclinical Drug Metabolism and Pharmacokinetics (A.T., R.d.K.), Preclinical Pharmacology (C.R., F.J.), Biology (J.G.), Chemistry (C.B.), Clinical Pharmacology (C.M.), and Preclinical Development (M.v.R., B.S.), Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland; Center for Human Drug Research, Leiden, The Netherlands (J.v.G.)
Ruben de Kanter
Departments of Preclinical Drug Metabolism and Pharmacokinetics (A.T., R.d.K.), Preclinical Pharmacology (C.R., F.J.), Biology (J.G.), Chemistry (C.B.), Clinical Pharmacology (C.M.), and Preclinical Development (M.v.R., B.S.), Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland; Center for Human Drug Research, Leiden, The Netherlands (J.v.G.)
Catherine Roch
Departments of Preclinical Drug Metabolism and Pharmacokinetics (A.T., R.d.K.), Preclinical Pharmacology (C.R., F.J.), Biology (J.G.), Chemistry (C.B.), Clinical Pharmacology (C.M.), and Preclinical Development (M.v.R., B.S.), Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland; Center for Human Drug Research, Leiden, The Netherlands (J.v.G.)
John Gatfield
Departments of Preclinical Drug Metabolism and Pharmacokinetics (A.T., R.d.K.), Preclinical Pharmacology (C.R., F.J.), Biology (J.G.), Chemistry (C.B.), Clinical Pharmacology (C.M.), and Preclinical Development (M.v.R., B.S.), Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland; Center for Human Drug Research, Leiden, The Netherlands (J.v.G.)
Christoph Boss
Departments of Preclinical Drug Metabolism and Pharmacokinetics (A.T., R.d.K.), Preclinical Pharmacology (C.R., F.J.), Biology (J.G.), Chemistry (C.B.), Clinical Pharmacology (C.M.), and Preclinical Development (M.v.R., B.S.), Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland; Center for Human Drug Research, Leiden, The Netherlands (J.v.G.)
Markus von Raumer
Departments of Preclinical Drug Metabolism and Pharmacokinetics (A.T., R.d.K.), Preclinical Pharmacology (C.R., F.J.), Biology (J.G.), Chemistry (C.B.), Clinical Pharmacology (C.M.), and Preclinical Development (M.v.R., B.S.), Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland; Center for Human Drug Research, Leiden, The Netherlands (J.v.G.)
Benno Schindelholz
Departments of Preclinical Drug Metabolism and Pharmacokinetics (A.T., R.d.K.), Preclinical Pharmacology (C.R., F.J.), Biology (J.G.), Chemistry (C.B.), Clinical Pharmacology (C.M.), and Preclinical Development (M.v.R., B.S.), Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland; Center for Human Drug Research, Leiden, The Netherlands (J.v.G.)
Clemens Muehlan
Departments of Preclinical Drug Metabolism and Pharmacokinetics (A.T., R.d.K.), Preclinical Pharmacology (C.R., F.J.), Biology (J.G.), Chemistry (C.B.), Clinical Pharmacology (C.M.), and Preclinical Development (M.v.R., B.S.), Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland; Center for Human Drug Research, Leiden, The Netherlands (J.v.G.)
Joop van Gerven
Departments of Preclinical Drug Metabolism and Pharmacokinetics (A.T., R.d.K.), Preclinical Pharmacology (C.R., F.J.), Biology (J.G.), Chemistry (C.B.), Clinical Pharmacology (C.M.), and Preclinical Development (M.v.R., B.S.), Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland; Center for Human Drug Research, Leiden, The Netherlands (J.v.G.)
Francois Jenck
Departments of Preclinical Drug Metabolism and Pharmacokinetics (A.T., R.d.K.), Preclinical Pharmacology (C.R., F.J.), Biology (J.G.), Chemistry (C.B.), Clinical Pharmacology (C.M.), and Preclinical Development (M.v.R., B.S.), Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland; Center for Human Drug Research, Leiden, The Netherlands (J.v.G.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Role of Physiology-Based Modeling in ACT-541468 Discovery
Alexander Treiber, Ruben de Kanter, Catherine Roch, John Gatfield, Christoph Boss, Markus von Raumer, Benno Schindelholz, Clemens Muehlan, Joop van Gerven and Francois Jenck
Journal of Pharmacology and Experimental Therapeutics September 1, 2017, 362 (3) 489-503; DOI: https://doi.org/10.1124/jpet.117.241596
Research ArticleDrug Discovery and Translational Medicine
Role of Physiology-Based Modeling in ACT-541468 Discovery
Alexander Treiber, Ruben de Kanter, Catherine Roch, John Gatfield, Christoph Boss, Markus von Raumer, Benno Schindelholz, Clemens Muehlan, Joop van Gerven and Francois Jenck
Journal of Pharmacology and Experimental Therapeutics September 1, 2017, 362 (3) 489-503; DOI: https://doi.org/10.1124/jpet.117.241596
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement